Scholarlink

Background <p>Older patients on dialysis have a complex regimen of drugs to manage their chronic kidney disease (CKD), associated complications, and co-morbidities. Our aim was to describe drug use in the year before and after dialysis initiation in the older population.</p> Methods <p>We included all patients aged ≥ 65&#xa0;years initiating chronic dialysis in France between 2010 and 2019 identified from the national kidney replacement therapy registry and matched with the national health data system. Drug use prevalence was described by pharmacotherapeutic classes, based on anatomical therapeutic chemical codes, and estimated quarterly for patients with ≥ 1 drug dispensing in the year before and after the initiation of dialysis. Analysis was stratified according to dialysis modality, sex, and age at dialysis initiation.</p> Results <p>Among 55,238 patients included, hyper-polypharmacy (≥ 10 drugs) rose to 76% at dialysis initiation, and slightly decreasing afterwards. Non-CKD-related drugs, including insulins, psychotropic, analgesic and non-antihypertensive cardiovascular drugs, showed stable prevalence, except for proton pump inhibitors (PPI) use which rose sharply before dialysis (40.8% to 54.8%) and then stabilized. Conversely, CKD-related drugs varied. At dialysis initiation, antihypertensives (except diuretics), potassium binders, and hypouricemic agents use declined, while calcium supplementation rose then stabilized. Vitamin D and phosphate binder use increased steadily. Trends in drug use patterns were similar across dialysis modality, sex and age.</p> Conclusion <p>Prescription changes occur at dialysis initiation, particularly for CKD-related drugs. Hyperpolypharmacy was highly prevalent, yet much of it is likely appropriate given the complex clinical profile of older dialysis patients. Further work is needed to explain the high prevalence of PPI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug prescription before and after dialysis initiation in older patients: a nationwide study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月11日

查看全文
  • Léa Faure,
  • Pernelle Noize,
  • Cécile Couchoud,
  • Emilie Hucteau,
  • Jessica Berdougo,
  • Florent Guerville,
  • Jerome Harambat,
  • Christian Combe,
  • Hélène Levassort,
  • Olivier Moranne,
  • Aghilès Hamroun,
  • Jean-Baptiste Beuscart,
  • Karen Leffondré,
  • Mathilde Prezelin-Reydit

摘要

Background

Older patients on dialysis have a complex regimen of drugs to manage their chronic kidney disease (CKD), associated complications, and co-morbidities. Our aim was to describe drug use in the year before and after dialysis initiation in the older population.

Methods

We included all patients aged ≥ 65 years initiating chronic dialysis in France between 2010 and 2019 identified from the national kidney replacement therapy registry and matched with the national health data system. Drug use prevalence was described by pharmacotherapeutic classes, based on anatomical therapeutic chemical codes, and estimated quarterly for patients with ≥ 1 drug dispensing in the year before and after the initiation of dialysis. Analysis was stratified according to dialysis modality, sex, and age at dialysis initiation.

Results

Among 55,238 patients included, hyper-polypharmacy (≥ 10 drugs) rose to 76% at dialysis initiation, and slightly decreasing afterwards. Non-CKD-related drugs, including insulins, psychotropic, analgesic and non-antihypertensive cardiovascular drugs, showed stable prevalence, except for proton pump inhibitors (PPI) use which rose sharply before dialysis (40.8% to 54.8%) and then stabilized. Conversely, CKD-related drugs varied. At dialysis initiation, antihypertensives (except diuretics), potassium binders, and hypouricemic agents use declined, while calcium supplementation rose then stabilized. Vitamin D and phosphate binder use increased steadily. Trends in drug use patterns were similar across dialysis modality, sex and age.

Conclusion

Prescription changes occur at dialysis initiation, particularly for CKD-related drugs. Hyperpolypharmacy was highly prevalent, yet much of it is likely appropriate given the complex clinical profile of older dialysis patients. Further work is needed to explain the high prevalence of PPI.